{"protocolSection":{"identificationModule":{"nctId":"NCT00864721","orgStudyIdInfo":{"id":"06-135"},"secondaryIdInfos":[{"id":"GA6181UU","type":"OTHER","domain":"Pfizer"}],"organization":{"fullName":"US Oncology Research","class":"INDUSTRY"},"briefTitle":"Sunitinib Non Small Cell Lung Cancer Patients Over 70","officialTitle":"Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70"},"statusModule":{"statusVerifiedDate":"2018-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-02"},"primaryCompletionDateStruct":{"date":"2012-07","type":"ACTUAL"},"completionDateStruct":{"date":"2012-07","type":"ACTUAL"},"studyFirstSubmitDate":"2009-03-18","studyFirstSubmitQcDate":"2009-03-18","studyFirstPostDateStruct":{"date":"2009-03-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-01-20","resultsFirstSubmitQcDate":"2018-10-12","resultsFirstPostDateStruct":{"date":"2018-10-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-10-12","lastUpdatePostDateStruct":{"date":"2018-10-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"US Oncology Research","class":"INDUSTRY"},"collaborators":[{"name":"Pfizer","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.","detailedDescription":"In this trial, the activity and tolerability of sunitinib malate (Sutent) will be examined in previously untreated elderly patients (\\>70 years old) felt not to be candidates for standard cytotoxic chemotherapy."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"],"keywords":["Untreated NSCLC in patients > 70"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":63,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Sunitinib Malate","type":"EXPERIMENTAL","description":"Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.","interventionNames":["Drug: Sutent"]}],"interventions":[{"type":"DRUG","name":"Sutent","description":"Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.","armGroupLabels":["Sunitinib Malate"],"otherNames":["sunitinib malate"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Disease Control Rate (DCR)","description":"Disease control rate = CR + PR + SD\\>=6-weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD) is defined as persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.","timeFrame":"Every 6 weeks until progressive disease or death due to any cause, up to 36 month."}],"secondaryOutcomes":[{"measure":"Overall Response Rates (OR)","description":"Overall response rates = CR + PR. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","timeFrame":"Every 6 weeks until progressive disease or death due to any causes, up to 36 months."},{"measure":"Progression-free Survival (PFS)","description":"PFS is measured from the date of registration to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at the date of last contact. Progressive disease (PD) is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.","timeFrame":"All patients were followed until progressive disease or death, up to 36 months."},{"measure":"1-year Overall Survival (OS) Rate.","description":"OS is measured from the date of registration to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the date of last contact.","timeFrame":"All patients were followed until death or up to 36 months."},{"measure":"Time to Progression (TTP)","description":"TTP is measured from the date of registration to the date of first documented disease progression or date of death due to progressive disease, whichever comes first. If a patient neither progresses nor dies due to progressive disease, this patient will be censored at the date of last contact. Progressive disease is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.","timeFrame":"All patients were followed until progressive disease or death, up to 36 months."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has measurable, metastatic NSCLC, other elderly NSCLC patients over 70 years of age who are not felt to be candidates for standard chemotherapy at the discretion of the treating physician may also be enrolled as long as they meet the criteria; these \"special consideration\" patients enrollment in the study must be approved by Dr. Reynolds or DR. Smith in Dr. Reynolds absence. Patients must have a nonsquamous histology to be eligible for this study.\n* Has not received any prior chemotherapy for the current disease.\n* Has an ECOG Performance status. Is 70 years of age or older.Has resolution of all acute toxic effects of radiotherapy or surgical procedures to NCI CTCAE.\n* If fertile, patient (males only) has agreed to an acceptable method of birthcontrol to avoid pregnancy for the duration of the study and for a period of 2 months thereafter.\n* Has signed the most recent Patient Informed Consent Form. Has signed a Pate int Authorization Form.\n\nExclusion Criteria:\n\n* Has predominantly squamous NSCLC histology.\n* Had prior treatment with study drugs or other drugs.\n* Has a history of hypersensitivity to any component of the study drug. Has any evidence of an of antecedent hemoptysis, squamous histology, or ongoing anticoagulation or clotting diathesis.\n* Pre-existing hemoptysis Grade 2, cavitating lesions or clear proximity or involvement of blood vessels.\n* Has had major surgery or radiation therapy within 4 weeks of starting the study treatment.\n* Has had NCI CTCAE (Version 3.0) Grade 3-4 hemorrhage within 4 weeks of starting the study treatment.\n* Has a history of or known spinal cord compression, or carcinomatous meningitis, or evidence of symptomatic brain or leptomeningeal disease on screening CT or MRI scan; however, treated, stable, and asymptomatic brain metastases are allowed.\n* Has had any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism. Has ongoing cardiac dysrhythmias of NCI CTCAE (Version 3.0) Grade 2.\n* Has prolonged QTc interval on baseline EKG. Has uncontrolled hypertension.\n* Has pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication.\n* Is receiving concurrent treatment on another clinical trial.\n* Supportive care trials or non-treatment trials, (eg, QOL), are allowed.\n* Is receiving concurrent immunotherapy, hormonal therapy, or radiation therapy.\n* Is receiving concurrent investigational therapy or has received such therapy within the past 30 days.\n* Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection.\n* Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs.\n* Is unable to comply with requirements of study","healthyVolunteers":false,"sex":"ALL","minimumAge":"70 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Craig H. Reynolds, MD","affiliation":"US Oncology Research, LLC; Ocala Oncology Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Ocala Oncology Center","city":"Ocala","state":"Florida","zip":"34471","country":"United States","geoPoint":{"lat":29.1872,"lon":-82.14009}},{"facility":"Cancer Centers of Florida, P.A.","city":"Ocoee","state":"Florida","zip":"34761","country":"United States","geoPoint":{"lat":28.56917,"lon":-81.54396}},{"facility":"Minnesota Oncology Hematology, P.A.","city":"Minneapolis","state":"Minnesota","zip":"55404","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Cancer Centers of North Carolina","city":"Raleigh","state":"North Carolina","zip":"27607","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"Willamette Valley Cancer Institute and Research Center","city":"Eugene","state":"Oregon","zip":"97401-8122","country":"United States","geoPoint":{"lat":44.05207,"lon":-123.08675}},{"facility":"Cancer Centers of the Carolinas","city":"Greenville","state":"South Carolina","zip":"29605","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"Texas Oncology - Arlington South","city":"Arlington","state":"Texas","zip":"76014","country":"United States","geoPoint":{"lat":32.73569,"lon":-97.10807}},{"facility":"Texas Oncology, P.A. - Bedford","city":"Bedford","state":"Texas","zip":"76022","country":"United States","geoPoint":{"lat":32.84402,"lon":-97.14307}},{"facility":"Methodist Charlton Cancer Ctr.","city":"Dallas","state":"Texas","zip":"75237","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Texas Cancer Center of Mesquite","city":"Mesquite","state":"Texas","zip":"75150","country":"United States","geoPoint":{"lat":32.7668,"lon":-96.59916}},{"facility":"Texas Oncology Cancer Care and Research Center","city":"Waco","state":"Texas","zip":"76712","country":"United States","geoPoint":{"lat":31.54933,"lon":-97.14667}},{"facility":"Virginia Oncology Associates","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"Yakima Valley Mem Hosp/North Star Lodge","city":"Yakima","state":"Washington","zip":"98902","country":"United States","geoPoint":{"lat":46.60207,"lon":-120.5059}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Sunitinib Malate","description":"Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.\n\nSutent: Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"63"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"29"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"34"}]}],"dropWithdraws":[{"type":"Patient request","reasons":[{"groupId":"FG000","numSubjects":"11"}]},{"type":"Hospitalized","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Drug hold/delay more than 4 weeks","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"21"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"ITT population","groups":[{"id":"BG000","title":"Sunitinib Malate","description":"Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.\n\nSutent: Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"63"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"78.7","spread":"5.08"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"31"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"32"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"60"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"63"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Disease Control Rate (DCR)","description":"Disease control rate = CR + PR + SD\\>=6-weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD) is defined as persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.","populationDescription":"Evaluable population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Every 6 weeks until progressive disease or death due to any cause, up to 36 month.","groups":[{"id":"OG000","title":"Sunitinib Malate","description":"Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.\n\nSutent: Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","lowerLimit":"49.9","upperLimit":"75.4"}]}]}]},{"type":"SECONDARY","title":"Overall Response Rates (OR)","description":"Overall response rates = CR + PR. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","populationDescription":"Evaluable population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Every 6 weeks until progressive disease or death due to any causes, up to 36 months.","groups":[{"id":"OG000","title":"Sunitinib Malate","description":"Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.\n\nSutent: Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"1.8","upperLimit":"16.2"}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"PFS is measured from the date of registration to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at the date of last contact. Progressive disease (PD) is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"All patients were followed until progressive disease or death, up to 36 months.","groups":[{"id":"OG000","title":"Sunitinib Malate","description":"Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.\n\nSutent: Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"0.1","upperLimit":"25.1"}]}]}]},{"type":"SECONDARY","title":"1-year Overall Survival (OS) Rate.","description":"OS is measured from the date of registration to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the date of last contact.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants alive at 1yr","timeFrame":"All patients were followed until death or up to 36 months.","groups":[{"id":"OG000","title":"Sunitinib Malate","description":"Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.\n\nSutent: Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","lowerLimit":"16","upperLimit":"38"}]}]}]},{"type":"SECONDARY","title":"Time to Progression (TTP)","description":"TTP is measured from the date of registration to the date of first documented disease progression or date of death due to progressive disease, whichever comes first. If a patient neither progresses nor dies due to progressive disease, this patient will be censored at the date of last contact. Progressive disease is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"All patients were followed until progressive disease or death, up to 36 months.","groups":[{"id":"OG000","title":"Sunitinib Malate","description":"Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.\n\nSutent: Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"0.1","upperLimit":"25.1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"During the whole treatment period, up to 30 days following last dose.","description":"For treated patients only, assessed at each treatment visit.","eventGroups":[{"id":"EG000","title":"Sunitinib Malate","description":"Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.\n\nSutent: Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.","seriousNumAffected":11,"seriousNumAtRisk":60,"otherNumAffected":45,"otherNumAtRisk":60}],"seriousEvents":[{"term":"ABDOMINAL PAIN","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"ANEMIA HEMOLYTIC (NOS)","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"APPETITE DECREASED","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60}]},{"term":"BLEEDING GASTROINTESTINAL","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"CARDIAC FAILURE","organSystem":"Cardiac disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"COLITIS ULCERATIVE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"DEHYDRATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60}]},{"term":"DIARRHEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":60}]},{"term":"DIVERTICULITIS","organSystem":"Infections and infestations","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"FATIGUE","organSystem":"General disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60}]},{"term":"HEMORRHAGE (NOS)","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"JAUNDICE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"MUCOSITIS ORAL","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"PAIN HEAD","organSystem":"General disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60}]},{"term":"THROMBOCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"VOMITING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60}]}],"otherEvents":[{"term":"ANEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":60}]},{"term":"ANOREXIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":13,"numAtRisk":60}]},{"term":"CONSTIPATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":60}]},{"term":"DEHYDRATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":60}]},{"term":"DIARRHEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":18,"numAtRisk":60}]},{"term":"DYSGUESIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":60}]},{"term":"ERYTHEMA","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"FATIGUE","organSystem":"General disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":26,"numAtRisk":60}]},{"term":"GASTROESOPHAGEAL REFLUX","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":60}]},{"term":"HEADACHE","organSystem":"General disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"INFECTION FUNGAL","organSystem":"Infections and infestations","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":60}]},{"term":"INSOMNIA","organSystem":"General disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":60}]},{"term":"MUCOSITIS","organSystem":"Infections and infestations","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":14,"numAtRisk":60}]},{"term":"MUSCLE WEAKNESS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":60}]},{"term":"NAUSEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":14,"numAtRisk":60}]},{"term":"NEUROPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":60}]},{"term":"NEUTROPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":60}]},{"term":"PAIN MOUTH","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":60}]},{"term":"PROTEINURIA","organSystem":"Renal and urinary disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":60}]},{"term":"RASH","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":60}]},{"term":"THROMBOCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":16,"numAtRisk":60}]},{"term":"VOMITING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":60}]},{"term":"WEAKNESS","organSystem":"General disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":60}]},{"term":"WEIGHT LOSS","organSystem":"General disorders","sourceVocabulary":"COSTART, CTCAE v3.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":60}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Craig Reynolds","organization":"Ocala Oncology, Ocala, FL, USA","email":"Craig.Reynolds@USOncology.com","phone":"352-732-4032"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077210","term":"Sunitinib"}],"ancestors":[{"id":"D011758","term":"Pyrroles"},{"id":"D001393","term":"Azoles"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D007211","term":"Indoles"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"}]}},"hasResults":true}